The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy

Area of Science:

• Pediatric Pharmacology
• Clinical Pharmacology
• Drug Development

Background:

• Pediatrics is recognized as a critical population for whom rational pharmacotherapy is needed, yet guidance is often lacking.
• Despite regulatory efforts in the US and Europe, a gap persists between awareness and implementation of evidence-based drug development and pharmacotherapy in children.
• Current approaches often rely on empiricism, necessitating a shift towards incorporating biologic knowledge of physiological maturation and adult data.

Purpose of the Study:

• To highlight the need for improved, science-based drug development and pharmacotherapy in pediatric populations.
• To explore the potential of modeling and simulation approaches to guide pediatric drug therapy.
• To emphasize the importance of educating pediatric caregivers on clinical pharmacology principles.

Main Methods:

• Review of current challenges and initiatives in pediatric drug development and pharmacotherapy.
• Discussion of the potential role of modeling and simulation (in silico approaches) in pediatric drug research.
• Emphasis on integrating biologic knowledge and adult data into pediatric drug development.

Main Results:

• Significant progress in recognizing the need for pediatric pharmacotherapy, but implementation lags behind awareness.
• Modeling and simulation show promise in identifying necessary data and studies for pediatric drug therapy.
• In silico approaches can aid in educating healthcare providers on pediatric clinical pharmacology.

Conclusions:

• A transition from empiricism to a knowledge-based approach is essential for rational pediatric pharmacotherapy.
• Modeling and simulation are valuable tools to facilitate this transition and benefit pediatric patients.
• Enhanced education in clinical pharmacology principles is crucial for optimizing drug therapy in children.